Program
mirikizumab
Also written as “Mirikizumab”, “LY3074828” and “Mirikizumab IV”.
Its studies are mostly in Colitis, Ulcerative · Psoriasis · Crohn Disease · Breast Feeding, led by 2 companies.
Drug pageMirikizumab: every studyAll 44 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lillyits history only | 356 open or running | phase 4since May 21, 2026 | Sep 18, 2013 | Feb 2027phase 1 · NCT07446101 |
| Rubix LS | 11 open or running | phase 4since Jul 1, 2025 | Jul 1, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Rubix LS only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2017Named mirikizumabINNProposed as its International Nonproprietary Name in WHO's List 117 · before, LY3074828
- Jul 1, 2025First study: phase 4 study in Crohn DiseaseFirst studyNCT07059130 · 150 planned · United States
TargetBeta
“Interleukin-23 inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| risankizumabrule | AbbVie | phase 4 | 68 |
| guselkumabrule | Johnson & Johnson | phase 4 | 60 |
Studies
The one study Rubix LS leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07059130Crohn Disease · United States | 4 | Not yet recruiting | Jan 1, 2026 | 150 |
How it is read
Names in the registry
- “Mirikizumab”, 24 entries
- “LY3074828”, 6 entries
- “Mirikizumab IV”, 3 entries
- “Mirikizumab SC”, 3 entries
- “Mirikizumab - SC”, 3 entries
Conditions, from the studies’ own filings
- Colitis, Ulcerative, 9 studies
- Psoriasis, 6 studies
- Crohn Disease, 5 studies
- Breast Feeding, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.